Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock announced that the FDA accepted the BLA for apitegromab with a PDUFA action date of September 30, 2026, bringing the company closer to launching the first muscle-targeted treatment for SMA. The company reported Q1 cash and marketable securities of $479.9 million, bolstered by a $100 million debt drawdown and $98 million in ATM proceeds during the quarter.
Key figures
- Revenue
- 0
- Drug Name
- apitegromab
- Phase Of Trial
- Phase 3
- Net loss
- 105500000
- Rd expense
- 51800000
- Atm proceeds
- 98000000
- Debt drawdown
- 100000000
- G and a expense
- 50200000
- Cash and equivalents
- 479900000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.